JACoW is a publisher in Geneva, Switzerland that publishes the proceedings of accelerator conferences held around the world by an international collaboration of editors.
@inproceedings{hu:cyclotrons2022-webi02,
author = {N.H. Hu and T. Aihara},
title = {{Compact Accelerator Based Epithermal Neutron Source and Its Application for Cancer Therapy}},
% booktitle = {Proc. CYCLOTRONS'22},
booktitle = {Proc. 23rd Int. Conf. Cyclotrons Appl. (CYCLOTRONS'22)},
pages = {176--178},
paper = {WEBI02},
language = {english},
keywords = {neutron, radiation, simulation, experiment, cyclotron},
venue = {Beijing, China},
series = {International Conference on Cyclotrons and their Applications},
number = {23},
publisher = {JACoW Publishing, Geneva, Switzerland},
month = {10},
year = {2023},
issn = {2673-5482},
isbn = {978-3-95450-212-7},
doi = {10.18429/JACoW-CYCLOTRONS2022-WEBI02},
url = {https://jacow.org/cyclotrons2022/papers/webi02.pdf},
abstract = {{The world’s first accelerator based epithermal neutron source for clinical boron neutron capture therapy (BNCT) was designed, developed, and commissioned between 2008 to 2010 by Sumitomo Heavy Industries in collaboration with Kyoto University at the Kyoto University Institute for Integrated Radiation and Nuclear Science. The cyclotron-based accelerator device can accelerate a proton up to an energy of roughly 30 MeV. When the proton contacts the beryllium target, fast neutrons are created that travel through a beam shaping assembly made of calcium fluoride, lead, iron, and aluminum to lower the neutron energy to the epithermal region, which is ideal for BNCT (10 keV). With a proton current of 1 mA, the system is intended to produce epithermal neutron flux of up to 1.2×10⁹ cm⁻² s⁻¹. In 2017, the same type of accelerator was installed at the Kansai BNCT Medical Center and in March 2020 the system received medical device approval in Japan (Sumitomo Heavy Industries, NeuCure® BNCT system). Soon after, BNCT for unresectable, locally advanced, and recurrent carcinoma of the head and neck region was approved by the Japanese government for reimbursement covered by the national health insurance system. Thus far, over 100 patients have been treated using this system.}},
}